In the BioHarmony Drug Report Database
Miltefosine
Impavido (miltefosine) is a small molecule pharmaceutical. Miltefosine was first approved as Impavido on 2014-03-19. It is used to treat cutaneous leishmaniasis, leishmaniasis, and visceral leishmaniasis in the USA. It is known to target RAC-alpha serine/threonine-protein kinase.
Trade Name
|
Impavido |
|---|---|
Common Name
|
miltefosine |
ChEMBL ID
|
CHEMBL125 |
Indication
|
cutaneous leishmaniasis, leishmaniasis, visceral leishmaniasis |
Drug Class
|
Phosphoro-derivatives |
Image (chem structure or protein)